PAX-1 is under clinical development by Komipharm International and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition ...
Pancreatic cancer can often be halted, but it's rarely detected in time.The largest gland in the human body produces enzymes and hormones that are vital for digestion and metabolism. However, it is ...
DIACC-3010 is under development for the treatment of gastric cancer and aggressive lymphomas. The drug candidate is administered through the oral route. It is a dual inhibitor of p70S6K/Akt1/3. It is ...